NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01667419,A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma,https://clinicaltrials.gov/study/NCT01667419,BRIM8,COMPLETED,"This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for recurrence. Participants will be enrolled in two separate cohorts: Cohort 1 will include participants with completely resected Stage IIC, IIIA (participants with one or more nodal metastasis greater than \[\>\] 1 millimeter \[mm\] in diameter), or IIIB cutaneous melanoma, as defined by the American Joint Committee on Cancer (AJCC) Classification, Version 7; Cohort 2 will include participants with Stage IIIC cutaneous melanoma, as defined by this classification scheme. Within each cohort, participants will be randomized (1:1 ratio) to receive vemurafenib or matching placebo over a 52-week period.",YES,Melanoma,DRUG: Vemurafenib|DRUG: Placebo,"Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT), DFS was defined as the time from randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause., From randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause (up to the April 17, 2017 data cut-off, approximately 4.5 years)","Distant Metastasis-Free Survival (DMFS) as Assessed Using Contrast-Enhanced MRI or Contrast Enhanced CT, DMFS was defined as the time from randomization until the date of diagnosis of distant (i.e. non-locoregional) metastases or death from any cause., From randomization until the date of diagnosis of distant (i.e., non-locoregional) metastases or death from any cause (up to the April 17, 2017 data cut-off, approximately 4.5 years)|Overall Survival (OS), OS is defined as the time from randomization until the date of death from any cause., From randomization until the date of death from any cause (up until 13-July-2018, approximately 6 years)|Percentage of Participants With Adverse Events, An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution., From randomization up to study completion or discontinuation (up until 13-July-2018, approximately 6 years)|Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) 30-Item Quality of Life Questionnaire (QLQ-C30) Score, European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire assesses 8 symptoms, function, financial difficulties, and a global health status/health-related quality of life (HRQoL). Most questions use a 4-point scale (1 'Not at all' to 4 'Very much';2 questions use a 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. Higher scores for the function and HRQoL represent higher levels of functioning and HRQoL, higher scores for the symptom represent higher levels of symptoms/problems, higher score for financial difficulty represent higher level of perceived financial burden of treatment. Changes of 5-10 points are considered to represent a minimally important difference to participants. A positive value means an increase, and negative value means a decrease in score at the indicated time-point relative to the score at baseline (Cycle 1 Day 1)., Day 1, Day 8, Day 15, Day 22 of Cycle 1;Day 1, Day 15 of Cycle 2;Day 1 Cycles 3-13;end of treatment(up to 13 months);every 13 weeks thereafter until recurrence or occurrence of a new primary melanoma (up to 17-Apr-17 data cut-off,approximately 4.5 years)|Plasma Concentration of Vemurafenib, Pre-morning dose (0 hour [hr]) and 1 to 4 hrs post-dose on Days 1, 8, 15, and 22 of Cycle 1; pre-morning dose (0 hr) on Days 1 and 15 of Cycle 2; pre-morning dose (0 hr) on Day 1 of Cycles 3-13; at end of treatment (up to 13 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,498,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",GO27826|2011-004011-24,2012-09-24,2017-06-23,2018-07-13,2012-08-17,2018-10-17,2019-07-23,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|UCLA Department of Medicine; Division of Hematology / Oncology, California City, California, 90095, United States|Kaiser Permanente - Hayward, Hayward, California, 94545, United States|UCLA Hematology Oncology - Irvine, Irvine, California, 92604, United States|UCSD Moores Cancer Center, La Jolla, California, 92093, United States|The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, 90025, United States|Cancer Center Of Santa Barbara; Network Clinical Research Specialist, Los Angeles, California, 90095, United States|TRIO-US Network Administration; Network Clinical Research Specialist, Los Angeles, California, 90095, United States|Kaiser Foundation Hospital - Oakland (W. MacArthur), Oakland, California, 94611, United States|Kaiser Permanente - Oakland, Oakland, California, 94611, United States|UCLA Healthcare/Pasadena Oncology, Pasadena, California, 91105, United States|Kaiser Permanente - Roseville, Roseville, California, 95661, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, 95814, United States|Kaiser Permanente, San Francisco, California, 94115, United States|K. Permanente - San Jose, San Jose, California, 95119, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, 93401, United States|Kaiser Permanente - Santa Clara, Santa Clara, California, 95051, United States|Kaiser Permanente - South San Francisco, South San Francisco, California, 94080, United States|Stanford University School of Medicine; Stanford Hospital Pharmacy, Stanford, California, 94305, United States|UCLA Cancer Center Hema/Oncol, Valencia, California, 91355, United States|Kaiser Permanente - Vallejo, Vallejo, California, 94589, United States|Kaiser Permanente - Walnut Creek, Walnut Creek, California, 94596, United States|UCLA Hematology Oncology - Westlake, Westlake Village, California, 91361, United States|University Of Colorado, Aurora, Colorado, 80045, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, 81501, United States|Florida Cancer Specialists - Broadway, Fort Myers, Florida, 33901, United States|Memorial Healthcare System, Hollywood, Florida, 33021, United States|GulfCoast Oncology, Sarasota, Florida, 34232, United States|Oncology Specialists, S.C., Park Ridge, Illinois, 60068, United States|Indiana University Health; Goshen Center for Cancer Care, Goshen, Indiana, 46526, United States|Indiana University Department of Medicine; Division of Infectious Diseases, Indianapolis, Indiana, 46202, United States|U of L - Physicians Pulmonology; Dept of Neuroradiology and Dept of Diagnostic Radiology, Louisville, Kentucky, 40202, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|St. Luke's Hospital, Kansas City, Missouri, 64111, United States|University of Kansas Medical Center; Cancer Center, Kansas City, Missouri, 64131, United States|Washington University; Dept of Medicine/Div of Medical Oncology, Saint Louis, Missouri, 63110, United States|Atlantic Health Systems; Pediatrics, Randolph, New Jersey, 07869, United States|New York University Medical Center PRIME; NYU Clinical Cancer Center, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Duke University Medical Center; Oncology, Durham, North Carolina, 27710, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, 19104, United States|MUSC Hollings Cancer Center/cannon Park Place; Attn: Tamara Saunders, Charleston, South Carolina, 29425, United States|West Clinic, Germantown, Tennessee, 38138, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, 37203, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Mary Babb Randolph Cancer Center, Morgantown, West Virginia, 26506, United States|Fundación CIDEA, Buenos Aires, C1425DTG, Argentina|Instituto Medico Especializado Alexander Fleming, Ciudad Autonoma Buenos Aires, 1426, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, C1284AEB, Argentina|Hospital Universitario Austral, Derqui-Pilar, B1629ODT, Argentina|Centro de Investigacion Pergamino SA, Pergamino, B2700CPM, Argentina|Instituto de Oncología de Rosario, Rosario, S2000KZE, Argentina|ISIS Clinica Especializada, Santa Fe, S3000, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Melanoma Institute Australia, North Sydney, New South Wales, 2060, Australia|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Border Medical Oncology, Wodonga, New South Wales, 3690, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, 2500, Australia|Cairns Base Hospital, Cairns, Queensland, 4870, Australia|The Townsville Hospital; Townsville Cancer Centre, Townsville, Queensland, 4812, Australia|Royal Adelaide Hospital; Hepatology, Adelaide, South Australia, 5000, Australia|Queen Elizabeth Hospital, Woodville, South Australia, 5011, Australia|Launceston General Hospital; Gastroenterology Research, Launceston, Tasmania, 7250, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Peninsula Oncology Centre; Frankston Private, Frankston, Victoria, 3199, Australia|Peter Maccallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Alfred Hospital, Melbourne, Victoria, 3004, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia|Medizinische Universität Innsbruck, Innsbruck, 6020, Austria|Klinikum Wels-Grieskirchen, Wels, 4600, Austria|Krankenanstalt Rudolfstiftung Wien, Wien, 1030, Austria|Medizinische Universität Wien, Wien, 1090, Austria|ZNA Middelheim, Antwerpen, 2020, Belgium|Institut Jules Bordet, Brussels, 1000, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|UZ Gent, Gent, 9000, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|AZ Groeninge, Apotheek, Kortrijk, 8500, Belgium|Trymed Clinical Research, Belo Horizonte, MG, 30150-281, Brazil|Hospital de Caridade de Ijuí, Ijuí, RO, 98700-000, Brazil|CITO - Centro Integrado de Terapia Onco-Hematológica - Hospital da Cidade de Passo Fundo, Passo Fundo, RS, 99010-260, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, 90035-003, Brazil|Clinica de Oncologia de Porto Alegre - CliniOnco, Porto Alegre, RS, 90430-090, Brazil|Hospital Sírio-Libanês, Sao Paulo, SP, 01308-050, Brazil|BC Cancer Agency Vancouver Centre - PARENT; BC Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada|Saint Boniface General Hospital; Section of Nephrology BG 007, Winnipeg, Manitoba, R2H 2A6, Canada|Saint John Regional Hospital; Department of Oncology, Saint John, New Brunswick, E2L 4L2, Canada|LHSC - Victoria Hospital; Department of Pediatrics, London, Ontario, N6A 4G5, Canada|The Ottawa Hospital Cancer Center; General Campus, Ottawa, Ontario, K1H 1C4, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, M4N3M50, Canada|Princess Margaret Hospital; Department of Med Oncology, Toronto, Ontario, M5G 2M9, Canada|CHUM Hôpital Notre-Dame, Montreal, Quebec, H2L 4M1, Canada|Mcgill University - Royal Victoria Hospital; Oncology, Montreal, Quebec, H3A 1A1, Canada|CHUQ - Hôtel-Dieu de Québec, Ste-Foy, Quebec, G1V 4G2, Canada|General Hospital Pula, Pula, 52100, Croatia|General Hospital Varazdin, Varazdin, 42000, Croatia|Clinical Hospital Center Sestre Milosrdnice, Zagreb, 10000, Croatia|Clinical Hospital Centre Zagreb, Zagreb, 10000, Croatia|Masarykuv onkologicky ustav, Brno, 656 53, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Fakultní nemocnice Olomouc, Olomouc, 775 20, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, 708 52, Czechia|Nemocnice Na Bulovce, Prague, 180 01, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, 100 34, Czechia|East Tallinn Central Hospital; Clinic of Internal Medicine, Tallinn, 11312, Estonia|North Estonia Medical Centre Foundation, Tallinn, 13419, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, 50406, Estonia|CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, 25030, France|Groupe Hospitalier Saint André - Hôpital Saint André, Bordeaux, 33075, France|Hôpital Ambroise Paré - Boulogne-Billancourt; Respiratory, Boulogne Billancourt, 92104, France|Hopital Claude Huriez - CHU Lille, Lille, 59037, France|Hopital de la Timone, Marseille, 13005, France|CHU NANTES - Hôtel Dieu; Pharmacy, Nantes, 44093, France|CHU Nice - Hopital de l'Archet 2, Nice, 06202, France|Hôpital Saint-Louis, Paris, 75475, France|Centre Hospitalier Lyon Sud, Pierre Benite, 69495, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, 76031, France|CHU de Toulouse - Hôpital Larrey, Toulouse, 31059, France|St. Josef-Hospital Universitaetsklinikum, Bochum, 44791, Germany|Elbekliniken Buxtehude GmbH, Buxtehude, 21614, Germany|Universitätsklinikum Essen, Essen, 45147, Germany|Universitaetsklinikum Frankfurt, Frankfurt, 60528, Germany|Universitätsklinikum Heidelberg, Heidelberg, 69120, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Kiel; Klinik fuer Allgemeine Innere Medizin, Kiel, 24105, Germany|Universitätsklinikum Koeln, Koeln, 50937, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Apotheke, Mainz, 55131, Germany|Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, 68167, Germany|Fachklinik Hornheide, Muenster, 48157, Germany|Universitätsklinikum Tübingen, Tuebingen, 72076, Germany|Universitätsklinikum Wurzburg, Würzburg, 97080, Germany|Cork University Hospital, Cork, Ireland|Mater Private Hospital, Dublin, 7, Ireland|The Mater Misericordiae Hospital, Dublin, 7, Ireland|University College Hospital, Galway, Ireland|Soroka Medical Center, Beer Sheva, 8410101, Israel|Rambam Health Care Campus, Haifa, 3109600, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|Rabin Medical Center-Beilinson Campus, Petach Tikva, 4941492, Israel|Chaim Sheba Medical Center, Ramat Gan, 5265601, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Lazio, 00133, Italy|Istituto Nazionale Tumori Regina Elena IRCCS, Roma, Lazio, 00144, Italy|IDI-Istituto Dermopatico dell'Immacolata IRCCS, Roma, Lazio, 00167, Italy|Istituto Nazionale per la Ricerca sul Cancro di Genova, Genova, Liguria, 16132, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Lombardia, 24127, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, 25100, Italy|Ospedale San Raffaele, Milano, Lombardia, 20132, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, 20141, Italy|IRCCS Istituto Clinico Humanitas; Farmacia, Rozzano, Lombardia, 20089, Italy|Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari, Bari, Puglia, 70126, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, 53100, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Veneto, 35128, Italy|Centro Oncologico Belenus, Cuernavaca, 62290, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, 44280, Mexico|Centro Regiomontano de Investigación Clínica, Monterrey, 64710, Mexico|Sanatorio la Luz, Morelia, 58260, Mexico|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|Leids Universitair Medisch Centrum; Cardiology, Leiden, 2333 ZA, Netherlands|Christchurch Hospital NZ, Christchurch, 8011, New Zealand|Wellington Hospital, Wellington, 6012, New Zealand|Stavanger Universitetssykehus, Helse Stavanger HF, Stavanger, 4011, Norway|SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie, Olsztyn, 10-228, Poland|Przychodnia Med-Polonia Sp. z o.o., Poznan, 60-693, Poland|Centrum Onkologii- Instytut; im. M.Skłodowskiej-Curie, Warszawa, 02-781, Poland|Dolnoslaskie Centrum Onkologii, Wroclaw, 53-439, Poland|IPO de Coimbra; Servico de Oncologia Medica, Coimbra, 3000-075, Portugal|Hospital do Espirito Santo; Servico de Oncologia Medica, Evora, 7000-811, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, 1649-035, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, 4200-072, Portugal|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, 143423, Russian Federation|Krasnodar City Oncology Center, Krasnodar, 350040, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, 115478, Russian Federation|Scientific Research Oncology Institute named after N.N. Petrov, St. Petersburg, 197758, Russian Federation|Institute of Oncology and Radiology of Serbia, Belgrade, 11000, Serbia|Military Medical Academy, Belgrade, 11040, Serbia|Clinical Center Bezanijska Kosa, Belgrade, 11070, Serbia|Institute for oncology of Vojvodina, Sremska Kamenica, 21204, Serbia|GVI Rondebosch Oncology Centre, Cape Town, 7700, South Africa|Mary Potter Oncology Centre, Groenkloof, 0181, South Africa|Groote Schuur Hospital Radiation Oncology Department; Department of Radiation Oncology, Observatory, 7925, South Africa|University of Pretoria Oncology Department, Pretoria, 0001, South Africa|Sandton Oncology Medical Group, Sandton, 2196, South Africa|Hospital Clinico Universitario de Santiago, Santiago de Compostela, LA Coruña, 15706, Spain|Hospital Costa del Sol; Servicio de Oncologia, Marbella, Malaga, 29600, Spain|Hospital de la Santa Creu; i Sant Pau, Barcelona, 08025, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, 08908, Spain|Hospital General Universitario Gregorio Marañon, Madrid, 28007, Spain|Hospital Universitari i Politecnic La Fe, Valencia, 46026, Spain|Länssjukhuset Ryhov, Jönköping, 551 85, Sweden|Norrlands Universitetssjukhus, Umea, 901 850, Sweden|Centrallasarettet Växjö, Växjö, 351 85, Sweden|CHUV; Departement d'Oncologie, Lausanne, 1011, Switzerland|CI Dnipropetrovsk CMCH 4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, 49102, Ukraine|Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, 79031, Ukraine|Bristol Haematology and Oncology Centre, Bristol, BS2 8ED, United Kingdom|Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|Western General Hospital, Edinburgh, EH4 2XU, United Kingdom|Queen Elizabeth Hospital, Kings Lynn, PE30 4ET, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, SE1 9RT, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, NG5 1PB, United Kingdom|Churchill Hospital, Oxford, OX3 7LJ, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LQ, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/19/NCT01667419/Prot_001.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/19/NCT01667419/SAP_002.pdf"
